skip to main content

PSMA-PET Staging — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardUrological CancersPSMA-PET StagingSCE Medical Oncology

A patient has metastatic castration-resistant prostate cancer with a pathogenic BRCA2 alteration and radiographic progression after enzalutamide. He is not currently in visceral crisis. Which biomarker-directed monotherapy is recommended by NICE TA887?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Olaparib monotherapy after enzalutamide progression

Option E is correct: TA887 recommends olaparib after progression on a newer hormonal treatment in BRCA1/2-mutated metastatic castration-resistant disease. Option A offers sequential androgen-receptor targeting. Option D would require a different biomarker context. Option C is not the TA887 treatment, and option B is not selected by BRCA2 status.

Reference: NICE TA887: olaparib in BRCA-positive metastatic prostate cancer. https://www.nice.org.uk/guidance/ta887/chapter/1-Recommendations